rs1967309

This variant is located in the ADCY9 gene.

▶

GWAS Catalog Trait Associations (3)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

monocyte percentage of leukocytes

Loya H et al. “A scalable variational inference approach for increased mixed-model association power.” Nature Genetics 57(2):461-468 (2025)
Allele G
OR 0.02
p 3.0e-16
N 394,642
Large GWAS
European

response to dalcetrapib, cardiovascular event measurement

Tardif JC et al. “Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.” Circulation. Cardiovascular Genetics 8(2):372-82 (2015)
Allele G
OR 1.54
p 2.0e-8
N 2,845
Large GWAS
European

monocyte count

Chen MH et al. “Trans-ethnic and Ancestry-Specific Blood-Cell Genetics in 746,667 Individuals from 5 Global Populations.” Cell 182(5):1198-1213.e14 (2020)
Allele G
OR —
p 4.0e-29
N 639,696
Large GWAS
multi-ancestry
Vuckovic D et al. “The Polygenic and Monogenic Basis of Blood Traits and Diseases.” Cell 182(5):1214-1231.e11 (2020)
Allele G
OR 0.02
p 1.0e-20
N 408,112
Large GWAS
European
Loya H et al. “A scalable variational inference approach for increased mixed-model association power.” Nature Genetics 57(2):461-468 (2025)
Allele G
OR 0.02
p 3.0e-19
N 394,642
Large GWAS
European
▶

Research that mentions this SNP (1)

▶
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease
AssociationN=6,147Nissen SE et al.(2018)· JAMA Cardiology

The dal-GenE trial tested whether dalcetrapib, a CETP inhibitor, reduces cardiovascular events in 6147 patients with acute coronary syndrome and the AA genotype at rs1967309 in the ADCY9 gene. The primary composite endpoint (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, or stroke) occurred in 9.5% of dalcetrapib-treated patients vs 10.6% of placebo-treated patients (hazard ratio 0.88, 95% CI 0.75-1.03, P = 0.12), which was not statistically significant, though a reduction in non-fatal myocardial infarction was observed (HR 0.79, 95% CI 0.65-0.96).

Traits studied:Acute coronary syndromeAtherosclerosisCardiovascular deathCardiovascular eventsMyocardial infarctionStroke
PubMedDOIMetascience Observatory

About ADCY9

Adenylate cyclase is a membrane bound enzyme that catalyses the formation of cyclic AMP from ATP. It is regulated by a family of G protein-coupled receptors, protein kinases, and calcium. The type 9 adenylyl cyclase is a widely distributed adenylyl cyclase, and it is stimulated by beta-adrenergic receptor activation but is insensitive to forskolin, calcium, and somatostatin. [provided by RefSeq, Jul 2008]

View all ADCY9 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…